Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | RAD51D |
| Variant | V200* |
| Impact List | nonsense |
| Protein Effect | loss of function |
| Gene Variant Descriptions | RAD51D V200* results in a premature truncation of the Rad51d protein at amino acid 200 of 328 (UniProt.org). V200* results in decreased Rad51d protein stability, impaired DNA homologous recombination activity and DNA damage response, and increased sensitivity to PARP inhibitors in culture (PMID: 33151324). |
| Associated Drug Resistance | |
| Category Variants Paths |
RAD51D mutant RAD51D inact mut RAD51D V200* |
| Transcript | NM_002878.4 |
| gDNA | chr17:g.35103522_35103523delGTinsTA |
| cDNA | c.598_599delGTinsTA |
| Protein | p.V200* |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_002878.3 | chr17:g.35103522_35103523delGTinsTA | c.598_599delGTinsTA | p.V200* | RefSeq | GRCh38/hg38 |
| NM_002878.4 | chr17:g.35103522_35103523delGTinsTA | c.598_599delGTinsTA | p.V200* | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51D V200* | triple-receptor negative breast cancer | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment inhibited viability of triple-negative breast cancer cells expressing RAD51D V200* in culture (PMID: 33151324). | 33151324 |